Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach.

Li L, Liu J, Yu W, Lou X, Huang B, Lin B.

Methods Mol Biol. 2013;1049:139-69. doi: 10.1007/978-1-62703-547-7_12.

PMID:
23913215
[PubMed - indexed for MEDLINE]
2.

Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies.

Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang JH, Hood L, Odunsi K, Lin B.

Gynecol Oncol. 2010 May;117(2):159-69. doi: 10.1016/j.ygyno.2010.01.041. Epub 2010 Feb 23.

PMID:
20181382
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B.

Mol Cell Proteomics. 2006 Mar;5(3):433-43. Epub 2005 Nov 30. Erratum in: Mol Cell Proteomics. 2006 Jun;5(6):1171.

PMID:
16319398
[PubMed - indexed for MEDLINE]
Free Article
4.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
[PubMed - indexed for MEDLINE]
5.

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Song J, Shih IeM, Chan DW, Zhang Z.

Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614.

PMID:
19484149
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.

Solár P, Sytkowski AJ.

Cancer Lett. 2011 Oct 1;309(1):11-8. doi: 10.1016/j.canlet.2011.05.008. Epub 2011 Jun 14.

PMID:
21676537
[PubMed - indexed for MEDLINE]
7.

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.

Cancer Res. 1996 Feb 1;56(3):556-62.

PMID:
8564971
[PubMed - indexed for MEDLINE]
Free Article
8.

Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.

Li L, Luan Y, Li X, Tang B, Zhang W, Li D, Zhao J, Wang G, Ding H, Reed E, Li QQ.

Oncol Rep. 2005 May;13(5):793-9.

PMID:
15809740
[PubMed - indexed for MEDLINE]
9.

Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.

Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, Kikuchi Y, Tenjin Y.

Hum Cell. 2001 Dec;14(4):305-15.

PMID:
11925933
[PubMed - indexed for MEDLINE]
10.

Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.

Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.

Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.

PMID:
18571892
[PubMed - indexed for MEDLINE]
11.

Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.

Lee PS, Teaberry VS, Bland AE, Huang Z, Whitaker RS, Baba T, Fujii S, Secord AA, Berchuck A, Murphy SK.

Int J Cancer. 2010 Mar 15;126(6):1378-89. doi: 10.1002/ijc.24797.

PMID:
19642140
[PubMed - indexed for MEDLINE]
12.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.

PMID:
21781307
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.

J Clin Oncol. 2007 Feb 10;25(5):517-25. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678.

PMID:
17290060
[PubMed - indexed for MEDLINE]
Free Article
14.

Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.

Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.

Oncol Rep. 2006 May;15(5):1265-71.

PMID:
16596196
[PubMed - indexed for MEDLINE]
15.

Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.

Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F.

Ann Oncol. 1998 Apr;9(4):423-30.

PMID:
9636834
[PubMed - indexed for MEDLINE]
Free Article
16.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
[PubMed - indexed for MEDLINE]
17.

Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.

Li J, Wood WH 3rd, Becker KG, Weeraratna AT, Morin PJ.

Oncogene. 2007 May 3;26(20):2860-72. Epub 2006 Oct 30.

PMID:
17072341
[PubMed - indexed for MEDLINE]
18.

Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.

Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O'Leary JJ, Gottesman M, Clynes M.

PLoS One. 2012;7(7):e40717. doi: 10.1371/journal.pone.0040717. Epub 2012 Jul 11.

PMID:
22792399
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].

Konno R.

Hum Cell. 2001 Dec;14(4):261-6. Review. Japanese.

PMID:
11925926
[PubMed - indexed for MEDLINE]
20.

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.

Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S.

Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.

PMID:
21487429
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk